Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cross Country Healthcare (CCRN) EBITDA (2016 - 2025)

Cross Country Healthcare's EBITDA history spans 16 years, with the latest figure at -$83.0 million for Q4 2025.

  • For Q4 2025, EBITDA fell 2084.96% year-over-year to -$83.0 million; the TTM value through Dec 2025 reached -$95.0 million, down 549.95%, while the annual FY2025 figure was -$95.0 million, 549.95% down from the prior year.
  • EBITDA reached -$83.0 million in Q4 2025 per CCRN's latest filing, down from -$4.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $77.6 million in Q4 2021 to a low of -$83.0 million in Q4 2025.
  • Average EBITDA over 5 years is $14.0 million, with a median of $12.2 million recorded in 2021.
  • Peak YoY movement for EBITDA: skyrocketed 6249.87% in 2021, then crashed 2084.96% in 2025.
  • A 5-year view of EBITDA shows it stood at $77.6 million in 2021, then plummeted by 53.22% to $36.3 million in 2022, then plummeted by 75.08% to $9.0 million in 2023, then plummeted by 141.97% to -$3.8 million in 2024, then plummeted by 2084.96% to -$83.0 million in 2025.
  • Per Business Quant, the three most recent readings for CCRN's EBITDA are -$83.0 million (Q4 2025), -$4.9 million (Q3 2025), and -$6.7 million (Q2 2025).